# US 12,110,323 B2 · Anti-human interleukin 17A monoclonal antibody and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,110,323 B2
- Document ID: US12110323B2
- Status: Granted
- Kind: B2
- Application number: 17/055,789
- Filed: 2018-05-17
- Published: 2021-07-29
- Granted: 2024-10-08
- Earliest claimed: 2018-05-17
- Assignees: Jiangsu Qyuns Therapeutics Co., Ltd.
- Applicants: Jiangsu Qyuns Therapeutics Co., Ltd.
- Inventors: Jiwan Qiu; Zhihua Qiu; Wei Chen; Tao Chen; Yong Kong; Yiliang Wu
- Web page: https://patentgrep.com/patent/US12110323B2

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed by the present invention are an anti-human interleukin 17A monoclonal antibody and an application thereof. The epitope of the monoclonal antibody binding to human interleukin 17A comprises 78th asparagine (N78). The antibody may be used to treat rheumatoid arthritis, psoriasis, multiple sclerosis, psoriatic arthritis, plaque psoriasis and/or ankylosing spondylitis.

## Claims

### Claim 1

An isolated anti-human interleukin 17A monoclonal antibody, which comprises three heavy chain complementarity determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementarity determining regions (CDR-L1, CDR-L2 and CDR-L3), wherein,
(a) an amino acid sequence of CDR-H1 is the amino acid sequence shown in SEQ ID NO: 1;
(b) an amino acid sequence of CDR-H2 is the amino acid sequence shown in SEQ ID NO: 2;
(c) an amino acid sequence of CDR-H3 is the amino acid sequence shown in SEQ ID NO: 3;
(d) an amino acid sequence of CDR-L1 is the amino acid sequence shown in SEQ ID NO: 4;
(e) an amino acid sequence of CDR-L2 is the amino acid sequence shown in SEQ ID NO: 5; and
(f) an amino acid sequence of CDR-L3 is the amino acid sequence shown in SEQ ID NO: 6.

### Claim 2 (depends on 1)

An isolated nucleic acid, encoding the monoclonal antibody according to claim 1.

### Claim 3 (depends on 1)

A pharmaceutical composition, comprising the monoclonal antibody according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 1)

A method of treating an autoimmune disease, which includes:
the monoclonal antibody according to claim 1 is administered to a subject in need thereof.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the autoimmune disease is rheumatoid arthritis, psoriasis, Crohn's disease, multiple sclerosis, psoriatic arthritis, plaque psoriasis and/or ankylosing spondylitis.

### Claim 6 (depends on 1)

The isolated anti-human interleukin 17A monoclonal antibody according to claim 1, comprising a heavy chain variable region with an amino acid sequence shown in SEQ ID NO:7 and a light chain variable region with an amino acid sequence shown in SEQ ID NO:8.

### Claim 7 (depends on 6)

The monoclonal antibody according to claim 6, comprising a heavy chain with an amino acid sequence shown in SEQ ID NO: 10 and a light chain with an amino acid sequence shown in SEQ ID NO:11.

### Claim 8 (depends on 6)

An isolated nucleic acid, encoding the monoclonal antibody according to claim 6.

### Claim 9 (depends on 6)

A pharmaceutical composition, comprising the monoclonal antibody according to claim 6 and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 6)

A method of treating an autoimmune disease, which includes:
the monoclonal antibody according to claim 6 is administered to a subject in need thereof.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the autoimmune disease is rheumatoid arthritis, psoriasis, Crohn's disease, multiple sclerosis, psoriatic arthritis, plaque psoriasis and/or ankylosing spondylitis.

### Claim 12 (depends on 1)

The isolated anti-human interleukin 17A monoclonal antibody according to claim 1, which binds to an epitope comprising amino acid residues 98-108 in the amino acid sequence of SEQ ID NO: 9.